Significantly, treatments with gefitinib combined with FGFR inhibitor LY2874455 and CCND1/CDK4 inhibitor abemaciclib induced strong and synergistic growth suppression in FGF3/4/19/CCND1-overexpressing gefitinib-resistant NSCLC cells in vitro and xenografts in vivo. This evidence concerns the gene FGF3 and non-small cell lung carcinoma.